FDA Approves Rydapt For Treatment Of Acute Myeloid Leukemia In Adult Patients The FDA approved the Novartis AG's Rydapt on April 28. The drug is targeted toward AML patients and the FDA lists it for $22,500 for an average 42-day treatment. by Andrew Norman